Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool April 20, 2004 Brian Gorman	PPD's New Possibilities The royalty stream from dapoxetine could significantly boost earnings.
The Motley Fool April 28, 2005 Brian Gorman	PPD Branches Out The company, which concentrates on running clinical trials for pharmaceutical and biotech clients is right in diversifying, but its strategy carries its own risk.
The Motley Fool October 18, 2005 Brian Gorman	PPD's Robust Pipeline The provider of drug development services continues to be a strong performer in its core business even as it demonstrates savvy in its new drug-partnering initiative. Investors, take note.
The Motley Fool April 18, 2006 Brian Gorman	PPD Develops Solid Growth The contract research firm cashes in on its core business. Investors celebrated Pharmaceutical Product Development's latest earnings release today by sending the stock up more than 9% in recent trading.
The Motley Fool October 17, 2006 Brian Gorman	PPD Disappoints? Not Quite Its discovery sciences business hindered results, but PPD remains a winner for investors.
The Motley Fool June 11, 2007 Brian Lawler	Johnson & Johnson's Pretty Pipeline While there are concerns about other parts of Johnson & Johnson (for example, its medical device segment), its pharmaceutical division has a robust pipeline of compounds in development that should pay off in the long haul.
The Motley Fool July 22, 2004 Brian Gorman	Stability for Covance? After a solid quarter, the drug development service company may have found a way to keep revenue consistent.
The Motley Fool August 3, 2004 Brian Gorman	PAREXEL Gets Leaner The research services provider continues to improve operating performance, but that might not affect its stock price.
The Motley Fool March 15, 2005 Lawrence Meyers	Pharma's Outsourcing Elixir Pharmaceutical Product Development saves the drug companies money. Solid financials suggest it's a prescription that's working. Investors who do their due diligence may also find a few dollars earned in their brokerage accounts as well.
The Motley Fool January 25, 2007 Brian Lawler	Johnson & Johnson's Earnings Glee Johnson & Johnson keeps growing, even if the pharmaceutical segment is a bit sluggish. Investors, take note.
The Motley Fool November 12, 2009 Brian Orelli	How Do You Say 'Drug Development' in Mandarin? Drug giant Novartis announces that it's heading to China in a big way.
The Motley Fool March 6, 2009 Brian Orelli	For Drug Companies, R&D Is Spelled C-R-O It seems likely that more and more pharma companies will try to get more bang for their bucks by spending them on research and development done outside the company, outsourcing it to clinical research organizations.
The Motley Fool July 1, 2004 Brian Gorman	Charles River's Big Buy Charles River Laboratories is buying Inveresk Research Group in what appears to be a bid to control more of the burgeoning market for preclinical drug development services.
The Motley Fool November 1, 2005 Brian Gorman	Kendle's Resurgence Can the contract pharmaceutical researcher continue its growth without more acquisitions? Despite the vibrant growth and its operational progress, Kendle still is at a disadvantage to larger rivals like Charles River Laboratories and PPD.
The Motley Fool February 12, 2007 Brian Lawler	I Love Drug Stocks This Valentine's Day, leave a special place in your heart for drug stocks.
The Motley Fool July 6, 2004 Brian Gorman	Hidden Drug Costs Regulatory requirements play an important role in drug expenses.
The Motley Fool March 28, 2005 Brian Gorman	A Passage to India? Changes in India's patent law could create new dynamics for the biotech and pharmaceutical industries. Investors should be on the lookout for the firms that seek to leverage these new opportunities.
The Motley Fool June 28, 2005 Lawrence Meyers	It's All Positive for PPDI Pharmaceutical Product Development continues to pump out the cash flow and rake in business. Investors, take note.
The Motley Fool October 3, 2011 Brian D. Pacampara	Pharmaceutical Product Development Shares Soared: What You Need to Know Shares of Pharmaceutical Product Development skyrocketed 25% Monday after The Carlyle Group and Hellman & Friedman LP agreed to buy the health-care research specialist for $3.8 billion.
Pharmaceutical Executive June 1, 2013	When Gurus Get It Wrong Despite their high status, management gurus aren't always on point when it comes to pharma, writes John Ansell.
The Motley Fool July 16, 2004 Rich Duprey	aaiPharma's Headache Lingers The tiny pharmaceutical company regains its ticker symbol, but controversy still reigns. Facing a raft of class action lawsuits, shareholders may wonder whether samples of painkiller Darvon will be included with their annual reports
Chemistry World October 11, 2007 Hepeng Jia	China's Drug Industry Set to Take Off Producing cheap drugs for the developing world could allow Chinese pharmaceutical firms to capture a bigger share of the international market, industry experts suggest.
The Motley Fool May 10, 2006 Brian Gorman	Charles River Restructures For the near term, restructuring plans should keep this one in limbo. Investors shouldn't expect too much from the company right now.
Registered Rep. March 1, 2005 David A. Twibell	What Ails You? Investors who are wary of big pharma investments have good reasons to be. But this does not mean that the sector is to be avoided at all costs. Indeed, for savvy, well-informed investors, now might be a good time to jump in.
Pharmaceutical Executive October 1, 2005 Philip A. George	Backpage: Under Surveillance Doctors and consumers don't doubt that pharma benefits society. But in the eyes of the public, industry efforts to monitor postmarket safety come up short.
The Motley Fool September 25, 2008 Brian Lawler	Eli Lilly's Dose of Disclosure The pharmaceutical pledges public reports of its dealings with doctors.
The Motley Fool November 30, 2010 Brian Orelli	A Witty Response to Pharma's R&D Dilemma According to GlaxoSmithKline CEO Andrew Witty, the pharmaceutical industry is a mess. That's the basic gist of his opinion piece in The Economist.
Reason April 2001 Ronald Bailey	Goddamn the Pusher Man Why does everybody seem to hate the pharmaceutical industry?
The Motley Fool November 2, 2004 Brian Gorman	aaiPharma Steadies Itself Investors applauded aaiPharma's restructuring, but the company has plenty of challenges ahead.